Materials & Resources » Chemicals | 3-D Matrix Ltd.

3-D Matrix Ltd. | Income Statement

Fiscal year is May-April. All values JPY Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
107,161.00
99,776.00
141,835.00
615,852.00
228,615.00
Cost of Goods Sold (COGS) incl. D&A
104,741.00
124,167.00
120,144.00
101,532.00
177,210.00
Gross Income
2,420.00
24,391.00
21,691.00
514,320.00
51,405.00
SG&A Expense
1,520,821.00
1,878,675.00
1,843,154.00
1,754,797.00
1,926,024.00
EBIT
1,518,401.00
1,903,066.00
1,821,463.00
1,240,477.00
1,874,619.00
Unusual Expense
-
195,008.00
526,199.00
121,198.00
97,936.00
Non Operating Income/Expense
5,438.00
113,547.00
117,653.00
28,653.00
114,661.00
Interest Expense
11,518.00
8,424.00
4,644.00
6,040.00
8,666.00
Pretax Income
1,523,867.00
1,990,220.00
2,462,025.00
1,391,361.00
1,865,007.00
Income Tax
1,507.00
4,745.00
2,698.00
1,210.00
1,209.00
Consolidated Net Income
1,525,374.00
1,994,965.00
2,459,327.00
1,392,571.00
1,866,217.00
Net Income
1,525,374.00
1,994,965.00
2,459,327.00
1,392,571.00
1,866,217.00
Net Income After Extraordinaries
1,525,374.00
1,994,965.00
2,459,327.00
1,392,571.00
1,866,217.00
Net Income Available to Common
1,525,374.00
1,994,965.00
2,459,327.00
1,392,571.00
1,866,217.00
EPS (Basic)
77.77
94.89
114.49
64.62
81.26
Basic Shares Outstanding
19,613.60
21,023.30
21,481.60
21,550.50
22,966.10
EPS (Diluted)
77.77
94.89
114.49
64.62
81.26
Diluted Shares Outstanding
19,613.60
21,023.30
21,481.60
21,550.50
22,966.10
EBITDA
1,416,845.00
1,780,444.00
1,725,003.00
1,240,477.00
1,874,619.00
Non-Operating Interest Income
614.00
2,731.00
7,934.00
5,009.00
1,553.00

About 3-D Matrix

View Profile
Address
Kojimachi HF Building, 7/F
Tokyo Tokyo 102
Japan
Employees -
Website http://www.3d-matrix.co.jp
Updated 09/14/2018
3-D Matrix Ltd. engages in the research and development, manufacture, and sale of medical products. It operates through the Medical Products Development and Sale, and Research Reagent Sales divisions. The Medical Products Development and Sale division includes surgery based on own organization's peptide technology, regenerative medicine, medical equipment, and pharmaceutical research and development.